TAT-SNX9

TAT-SNX9 is a cell-penetrating fusion peptide designed to selectively inhibit TGF-β signaling by blocking the nuclear translocation of Smad3. It consists of the HIV-1 trans-activator of transcription (TAT) protein sequence conjugated to a 30-amino acid fragment derived from sorting nexin 9 (SNX9). By specifically preventing Smad3 nuclear import without affecting Smad2, TAT-SNX9 inhibits the expression of TGF-β target genes such as fibronectin and reduces cell migration and invasion. It has been investigated in preclinical models of organ fibrosis and malignant gliomas (glioblastoma multiforme), where the TGF-β/Smad3 axis promotes tumor progression and resistance to therapy.

Other names

TAT-SNX9 peptideTAT-SNX-9 peptideTAT-SNX 9 peptideTAT-SNX9 fusion peptideTAT-SNX-9 fusion peptideTAT-SNX 9 fusion peptide